RxDoctor Payments Data

Swe Zin Mar Winhtut Oo, MD

Nephrology · Dayton, OHNPI 1396136875

Payments from drug & device makers

$872in general payments, 2019–2025

Across 37 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$208
  • Nxstage Medical, Inc.$136
  • Travere Therapeutics, Inc.$84
  • Medtronic$76
  • Bayer$66
  • Fresenius USA Marketing, Inc.$58
  • plus $244 from 9 others

What the payments were for

  • Food & beverage$84597%
  • Education$263%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$872 in reported general payments places this provider in the 40th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$174,846
Medicare patients
464
Services billed
1,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate30$10,975
Sevelamer Carbonate57$7,026
Clonidine36$3,237
SpsSodium Polystyrene Sulfon/Sorb12$1,923
Calcitriol165$1,422
Calcium Acetate19$1,293
Nifedipine ErNifedipine26$1,007
Hydralazine Hcl71$833
Potassium Citrate ErPotassium Citrate12$791
Allopurinol120$745
Doxazosin Mesylate33$675
Potassium Chloride31$573
Cinacalcet Hcl14$429
Furosemide110$426
Lisinopril127$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$208$10,97530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 450 nephrology providers in Ohio.

Other nephrology in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →